Genelux (GNLX) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Genelux (GNLX) over the past year, losing 18.2% versus a loss of 57.7%. NRX Pharmaceuticals is the larger company by market cap ($112.6 million vs $109.5 million), about 1.0 times the size. NRX Pharmaceuticals converts more of its revenue into profit, with a net margin of -2336.5% versus -401812.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | NRXP |
|---|---|---|
| Share price | $2.42 | $2.60 |
| Market cap | $109.49M | $112.57M |
| 1-day change | -2.42% | -4.06% |
| YTD return | -44.50% | -4.06% |
| 1-year return | -57.69% | -18.24% |
| 5-year return | — | -97.37% |
| EPS (TTM) | $-0.86 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.00K | $1.23M |
| Revenue growth (YoY) | 0.00% | — |
| Net income (latest FY) | $-32.15M | $-28.62M |
| Gross margin | — | 58.78% |
| Operating margin | -415175.00% | -1324.41% |
| Net margin | -401812.50% | -2336.49% |
| 52-week high | $8.54 | $5.06 |
| 52-week low | $2.29 | $1.62 |
| Distance from 52-week high | -71.65% | -48.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +678.10% | +1380.77% |
| Average volume | 288.93K | 860.32K |
| Shares outstanding | 45.25M | 43.30M |
| Employees | 25 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed GNLX by 39.5 percentage points over the past year.
- NRX Pharmaceuticals is more profitable, keeping -2336.5 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
GNLX vs NRXP FAQ
Which is bigger, Genelux or NRX Pharmaceuticals?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $112.57M compared with $109.49M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or NRXP?
NRXP returned -18.24% over the past 12 months, compared with -57.69% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.